Biocon Biologics and Viatris launch Abevmy in Canada
Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Abevmy
Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab
Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…
Biocon Biologics and Viatris get CHMP Nod for Abevmy
Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth